Magnesium-Engineered Silica Framework for pH-Accelerated Biodegradation and DNAzyme-Triggered Chemotherapy

Area of Science:

• Biomedical Engineering
• Materials Science
• Nanotechnology

Background:

• Inorganic nanocarriers show promise in preclinical theranostics but face challenges in biodegradability and targeted drug delivery.
• Poor biodegradability and premature drug leakage limit the clinical translation of current nanocarrier systems.

Purpose of the Study:

• To develop a novel nanocarrier system with enhanced biodegradability and controllable drug release for improved cancer theranostics.
• To address the limitations of existing inorganic nanocarriers for potential clinical applications.

Main Methods:

• Engineered mesoporous silica nanocarriers via direct magnesium doping using a dissolution and regrowth approach.
• Developed hollow mesoporous magnesium silicate nanoparticles (HMMSNs) that respond to acidic tumor microenvironments.
• Utilized Mg2+-dependent DNAzyme activation for triggered drug release from HMMSNs.

Main Results:

• Achieved facile biodegradation of magnesium silicate nanocarriers in mild acidic conditions.
• Demonstrated triggered anticancer drug release activated by tumor microenvironment and Mg2+.
• Showcased enhanced anticancer efficacy and high biocompatibility of the nanocarriers and their degradation products.

Conclusions:

• The engineered HMMSNs offer a biodegradable and intelligent platform for enhanced cancer theranostics.
• This strategy overcomes key hurdles for clinical translation, including biodegradability and controlled drug release.
• The nanocarriers and their byproducts are biocompatible and readily excreted, supporting their potential for clinical use.